Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neurocrine Closer To Ingrezza Label Expansion With Huntington’s Chorea Phase III Win

Executive Summary

The neuroscience-focused firm plans a 2022 supplemental NDA for Ingrezza following success in the pivotal KINECT-HD study. The biotech needed an R&D success after recent stumbles.

You may also be interested in...



Neurocrine’s Ingrezza Adds Huntington’s Indication, May Have Competitive Edge

The company’s VMAT2 inhibitor joins others in the drug class with a warning about suicidal ideation, but its once-daily dosing without titration may be an advantage in chorea associated with Huntington’s disease.

Another UK Biotech Snapped Up As Neurocrine Buys Diurnal

Lack of scale, the need for further funding and problems getting reimbursement for its adrenal insufficiency products left the Wales-headquartered firm vulnerable to a takeover and San Diego's Neurocrine has swooped.

New Player Joins Search For Effective Huntington's Therapies

Despite recent setbacks for Roche and Wave's respective antisense offerings, both those two firms and a number of other companies are trying a variety of approaches to find a treatment for Huntington's.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC145551

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel